News & Events

For Immediate Release

Bookmark & Share
Contact: Vicki Cohn, (914) 740-2156, vcohn@liebertpub.com
Emerging Role of MicroRNAs in Diabetes-Related Inflammation

New Rochelle, NY, November 1, 2012—Type 2 diabetes and the serious complications it can cause are reaching epidemic levels worldwide. Pre-diabetes and insulin resistance can precede the appearance of clinical disease by years or even decades. Since inflammation is now recognized as an important cause of type 2 diabetes, markers of diabetes-related inflammation such as microRNAs hold promise for early disease detection and interventions, and as valuable new targets for therapeutic drug discovery. These new findings are described in a review article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. The article is available free on the Nucleic Acid Therapeutics website.

 

Péter Hamar, Semmelweis University, Budapest, Hungary, summarizes recent research that support a critical role for microRNAs (miRNAs) in the inflammatory processes that contribute to the development of type 2 diabetes and its related complications. He explores how the ability to measure even small changes in the levels of specific miRNAs, which are small strands of nucleic acids that help to regulate gene expression in human cells, could have enormous clinical relevance by allowing for early interventions to delay or prevent the onset of type 2 diabetes. miRNAs may have value both as novel diagnostic tools and as new therapeutic targets for pre-diabetes, he concludes in "Role of Regulatory MicroRNAs in Type 2 Diabetes Mellitus-Related Inflammation."

 

“It is increasingly clear that diabetes is a collection of diseases at the level of molecular causes, and that microRNAs play a critical role both in the disease itself and thus in potential ways to address it. This review paper provides an excellent snapshot of our current knowledge,” says Executive Editor Fintan Steele, PhD, SomaLogic, Inc., Boulder, CO.


Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Fintan Steele, PhD, SomaLogic, Boulder, CO.

About the Journal
Nucleic Acid Therapeutics is an authoritative, peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. Nucleic Acid Therapeutics is the Official Journal of the Oligonucleotide Therapeutics Society. Complete tables of contents and a free sample issue may be viewed on the Nucleic Acid Therapeutics website.

About the Publisher
Mary Ann Liebert, Inc. publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy and Human Gene Therapy Methods, Diabetes Technology and Therapeutics, Metabolic Syndrome and Related Disorders, and DNA and Cell Biology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc. publishers website.